Clinically, NDUFB11 down-expression associates with atherosclerotic progression and adverse cardiovascular outcomes (Yang et al., 2023), which is particularly relevant given that 20% of IS originates from atherosclerotic plaque rupture and subsequent thromboembolism (Puig et al., 2023). This evidence concerns the gene NDUFB11 and Thromboembolism.